Exploring exosomes and immunotherapy for aggressive B-cell lymphomas
Exosomes and Resistance to Immunotherapy in Aggressive Non-Hodgkin B-cell Lymphomas (B-NHL)
NA · University Hospital, Limoges · NCT03985696
This study is testing how tiny particles from cancer cells might affect the success of immunotherapy and chemotherapy in people with aggressive B-cell lymphomas, to find better treatment options for those who aren't responding well to current therapies.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 90 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Limoges (other) |
| Drugs / interventions | rituximab, chemotherapy, immunotherapy |
| Locations | 1 site (Limoges) |
| Trial ID | NCT03985696 on ClinicalTrials.gov |
What this trial studies
This study investigates the role of exosomes in the treatment of aggressive non-Hodgkin B-cell lymphomas, particularly diffuse large B-cell lymphoma (DLBCL). It aims to understand how exosomes, which are microvesicles released by tumor B cells, may contribute to resistance against the commonly used immunotherapy, rituximab, in combination with CHOP chemotherapy. By analyzing blood samples from patients, the study seeks to identify the expression of therapeutic targets on exosomes and their potential as diagnostic markers. The ultimate goal is to enhance treatment strategies for patients who do not respond adequately to current therapies.
Who should consider this trial
Good fit: Ideal candidates include adults over 18 years old diagnosed with diffuse large B-cell lymphoma or those who have relapsed after R-CHOP therapy.
Not a fit: Patients with other B-cell diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies for patients with aggressive B-cell lymphomas, potentially increasing their chances of long-term remission.
How similar studies have performed: While the role of exosomes in cancer treatment is an emerging field, this specific approach to studying exosomes in relation to immunotherapy in B-NHL is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria : * patients over 18 years old with DLBCL at diagnostic or relapsed patients after R-CHOP therapy. * Healthy volunteers over 18 years old Exclusion Criteria: * other B cell diseases
Where this trial is running
Limoges
- University Hospital Limoges — Limoges, France (RECRUITING)
Study contacts
- Study coordinator: Julie ABRAHAM, Dr
- Email: julie.abraham@chu-limoges.fr
- Phone: +33 (0) 555 056 651
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Lymphoma, B-cell, Aggressive Non-Hodgkin, B cells, exosomes, immunotherapy, Lymphomas, DLBCL